In an interview with Private Equity International Magazine, Glenn Mincey – National Sector Leader of Private Equity, and Kristin Pothier – Global Healthcare and Life Sciences Strategy Leader at KPMG, discuss the hyper active deal market around ancillary care services and the impact of COVID-19 on this space.
Key interview takeaways:
- The variety of opportunities within ancillary care, as well as the its continued, essential position within the ecosystem of healthcare, make it attractive for private equity.
- Ancillary care is being fueled by technological innovation, both due to COVID, and what will be a new horizon post COVID. Private equity will flow in to help fund this technology.
- While COVID certainly put diagnostics center stage, therapeutic drugs of various sorts will be required more than ever as precision medicine continues its journey, providing on-going opportunity for investment and innovation far beyond COVID.
- Intense deal competition will not let up and valuations will remain high once out to bid.
The trend of increasing PE investment into these businesses is likely to continue
— Glenn Mincey, National Sector Leader of Private Equity
There has been intense competition from almost every single asset that we have come across
— Kristin Pothier, Global Healthcare and Life Sciences Strategy Leader
